Three different doses of Niktimvo all had high rates of response among patients with recurrent or refractory ...

A potentially life-saving cancer treatment is often referred to as the original immunotherapy and it helped pave the way for ...

Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of ...

Chronic graft-versus-host disease (GVHD) remains a rare and unacceptably debilitating autoimmune-like syndrome that afflicts patients in whom a blood disorder or cancer is otherwise cured by means ...

According to DelveInsight's estimates, in the 7MM, the total incident cases of aGvHD for Grade B, Grade C, and Grade D were around 6,000, 3,000, and 2000 , respectively, in 2023, which are expected to ...

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

Niktimvo is the second US FDA-approved therapy for chronic GvHD in Incyte’s portfolio. The other product, Jakafi (ruxolitinib), raked in $2.6bn in sales last year, as per Incyte’s financials.

The digital twin trial arm demonstrated a 52.7% overall response rate at 6 months for prednisone in chronic GVHD, aligning with real-world data.

An ongoing clinical trial at MSK is now looking at whether lower doses of chemotherapy are as effective as higher doses at ...

One study showed similar OS and GVHD relapse-free survival (GRFS) with matched or mismatched unrelated donor (MUD, MMUD) transplants. In contrast, the second study showed lower overall survival ...